Clearmind Medicine (NASDAQ:CMND) Posts Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) posted its quarterly earnings results on Monday. The company reported ($6.78) EPS for the quarter, Zacks reports.

Clearmind Medicine Stock Up 0.9%

Shares of NASDAQ:CMND traded up $0.03 during trading on Monday, hitting $3.37. 102,555 shares of the stock traded hands, compared to its average volume of 1,144,939. The company has a market cap of $3.43 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. The company has a fifty day moving average price of $6.22 and a two-hundred day moving average price of $16.48. Clearmind Medicine has a 52-week low of $2.10 and a 52-week high of $524.00.

Insider Buying and Selling at Clearmind Medicine

In other news, major shareholder Financial Lp Hrt bought 2,159,052 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was purchased at an average cost of $0.15 per share, with a total value of $323,857.80. Following the acquisition, the insider directly owned 2,063,266 shares in the company, valued at $309,489.90. This trade represents a -2,254.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.